IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1639-1645

  Rose, Thomas ^a   Grützkau, Andreas ^b   Hirseland, Heike ^b   Huscher, Dörte ^a,b   Dähnrich, Cornelia ^c   Dzionek, Andrzej ^d   Ozimkowski, Tobias ^d   Schlumberger, Wolfgang ^c   Enghard, Philipp ^b   Radbruch, Andreas ^b   Riemekasten, Gabriela ^a   Burmester, Gerd Rüdiger ^a   Hiepe, Falk ^a,b   Biesen, Robert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Leibniz Institute   (Germany)

^c Institute of Experimental Immunology   (Germany)

^d MILTENYI BIOTEC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SIALOADHESIN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; CHEMOKINES; CYTOKINES; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; FEMALE; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIALIC ACID BINDING IG-LIKE LECTIN 1; YOUNG ADULT;

EID: 84883769438     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201586     Document Type: Article

References (43)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39. (Pubitemid 351397092)
2. Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:455-60. (Pubitemid 19158931)
3. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90. (Pubitemid 44622099)
4. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68. (Pubitemid 28216666)
5. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
6. Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010;62:837-44.
7. Bruns A, Blass S, Hausdorf G, et al. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-15.
8. Ng KP, Manson JJ, Rahman A, et al. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900-4. (Pubitemid 44917463)
9. Biesen R, Dahnrich C, Rosemann A, et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R26.
10. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23:113-21.
11. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
12. Yao Y, Higgs BW, Richman L, et al. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010;12(Suppl 1):S6.
13. Jabs WJ, Hennig C, Zawatzky R, et al. Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res 1999;19:463-9. (Pubitemid 29269936)
14. von Wussow P, Jakschies D, Hochkeppel H, et al. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:914-18. (Pubitemid 19181015)
15. Preble OT, Rothko K, Klippel JH, et al. Interferon-induced 20-50 adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983;157:2140-6. (Pubitemid 13060909)
16. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-15. (Pubitemid 36297546)
17. Karonitsch T, Feierl E, Steiner CW, et al. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 2009;60:1463-71.
18. Smiljanovic B, Grun JR, Biesen R, et al. The multifaceted balance of TNF-alpha and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) Published Online First: May 2012. doi: 10.1007/s00109-012-0907-y.
19. Kim T, Kanayama Y, Negoro N, et al. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9. (Pubitemid 18013195)
20. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71. (Pubitemid 32011791)
21. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23. (Pubitemid 36350866)
22. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62. (Pubitemid 44497776)
23. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6.
24. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9.
25. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16. (Pubitemid 43877940)
26. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;63:1044-53.
27. Niewold TB, Adler JE, Glenn SB, et al. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008;58:2113-19. (Pubitemid 351988103)
28. Kong KO, Tan AW, Thong BY, et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009;156:134-40.
29. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098-107.
30. Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R90.
31. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136-45. (Pubitemid 351564017)
32. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
33. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom 2009;1:pii: 374312.
34. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
35. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
36. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902-6. (Pubitemid 41511186)
37. Cresswell L, Yee CS, Farewell V, et al. Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) 2009;48:1548-52.
38. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42:1372-9. (Pubitemid 37407029)
39. Lyons PA, McKinney EF, Rayner TF, et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis 2010;69:1208-13.
40. Avraamides G, Ng CY, David R, et al. IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration. J Interferon Cytokine Res 2007;27:291-303. (Pubitemid 46786931)
41. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:73ra20.
42. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8. (Pubitemid 9226519)
43. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-804.